Emerging therapies in Friedreich's ataxia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Klockgether T. Parkinsonism & related disorders. Ataxias. Pakinsonism Relat. Disord. 13, S391–S394 (2007).
  MedlineGoogle Scholar
• 2 Labuda M, Labuda D, Miranda C et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology 54, 2322–2324 (2000).
  Medline CASGoogle Scholar
• 3 Filla A, Michele G, Cavalcanti F et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 59, 554–560 (1996).
  Medline CASGoogle Scholar
• 4 Manto M, Marmolino D. Cerebellar ataxias. Curr. Opin. Neurol. 22, 419–429 (2009).
  MedlineGoogle Scholar
• 5 Dürr A, Cossee M, Agid Y et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169–1175 (1996).
  MedlineGoogle Scholar
• 6 Saute JAM, Donis KC, Serrano-Munuera C et al. Ataxia rating scales – psychometric profiles, natural history and their application in clinical trials. Cerebellum 11, 488–504 (2012). •• This is a comprehensive review of ataxia rating scales where the scales are systematically reviewed and critiqued.
  MedlineGoogle Scholar
• 7 Reetz K, Dogan I, Costa AS et al. Bilogical and clinical characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 14(2), 174–182 (2015).
  MedlineGoogle Scholar
• 8 Cano SJ, Riazi A, Schapira AH et al. Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies. Mov. Disord. 24(7), 984–992 (2009).
  MedlineGoogle Scholar
• 9 Trouillas P, Takayanagi T, Hallett M et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 145, 205–211 (1997).
  Medline CASGoogle Scholar
• 10 Bürk K, Schulz S, Schulz J. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J. Neurochem. 126(Suppl. 1), 118–124 (2013).
  Medline CASGoogle Scholar
• 11 Subramony SH, May W, Lynch D et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261–1262 (2005).
  Medline CASGoogle Scholar
• 12 Gillis JC, Benefield P, McTavish D. Idebenone: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5, 133–152 (1994).
  Medline CASGoogle Scholar
• 13 Lagedrost S, Sutton M, Cohen M et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month Phase III study (IONIA). Am. Heart J. 161, 639–645 (2011).
  Medline CASGoogle Scholar
• 14 Lynch DR, Perlman SL, Meier T. A phase 3 double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67(8), 941–947 (2010).
  MedlineGoogle Scholar
• 15 Hausse AO, Aggoun Y, Bonnet D et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart. 87, 346–349 (2002).
  Medline CASGoogle Scholar
• 16 Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60(10), 1676–1679 (2003).
  Medline CASGoogle Scholar
• 17 Pineda M, Arpa J, Montero R et al. Idebenone treatment in pediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470–475 (2008).
  MedlineGoogle Scholar
• 18 DiProspero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878–886 (2007).
  Medline CASGoogle Scholar
• 19 Lodi R, Hart PE, Rajagopalan B et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with ataxia. Ann. Neurol. 49(5), 590–596 (2001).
  Medline CASGoogle Scholar
• 20 Hart P, Lodi R, Rajagopalan B et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62(4), 621–626 (2005).
  MedlineGoogle Scholar
• 21 Cooper JM, Kolipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficiency of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15(12), 1371–1379 (2008).
  Medline CASGoogle Scholar
• 22 Lynch DR, Willi SM, Wilson RB et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov. Disord. 27(8), 1026–1033 (2012).
  Medline CASGoogle Scholar
• 23 Li L, Voullaire L, Sandi C et al. Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS ONE 8(2), e55910 (2013).
  MedlineGoogle Scholar
• 24 Yiu EM, Tai G, Peverill RE et al. An open-label trial in Friedreich ataxia suggest clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 262(5), 1344–1353 (2015).
  Medline CASGoogle Scholar
• 25 Schöls L, Zange J, Abele M et al. L-Carnitine and creatine in Friedreich's ataxia, A randomized, placebo-controlled crossover trial. J. Neural. Transm. 112, 789–796 (2005).
  Medline CASGoogle Scholar
• 26 Villa RF, Turpeenoja L, Benzi G, Giuffrida Stella AM. Action of actylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum. Neurochem. Res. 13(10), 909–916 (1988).
  Medline CASGoogle Scholar
• 27 Sorbi S, Forleo P, Fani C, Piacentini S. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin. Neuropharmacol. 23(2), 114–118 (2000).
  Medline CASGoogle Scholar
• 28 Pourcher E, Barbeau A. Field testing of an ataxia scoring and staging system. Can. J. Neurol. Sci. 7, 339–344 (1980).
  Medline CASGoogle Scholar
• 29 Angel RW. The rebound phenomenon of Gordon Holmes. Arch. Neurol. 34(4), 250 (1977).
  Medline CASGoogle Scholar
• 30 Albeti R, Uzun E, Renganathan I et al. Targeting lipid peroxidation and mitochondrial I mbalance in Friedreich's ataxia. Pharmacol. Res. 99, 344–350 (2015).
  MedlineGoogle Scholar
• 31 Hill S, Lamberson CR, Xu L, To R et al. Small amounts of isotopereinforced polyunsaturated fatty acids suppress lipid autoxidation. Free Radic. Biol. Med. 53(4), 893–906 (2012).
  Medline CASGoogle Scholar
• 32 Lamberson CR, Xu L, Muchalski H et al. Unusual kinetic isotope effects of deuterium reinforced polyunsaturated clinical features fatty acids in tocopherol-mediated free radical chain oxidations. J. Am. Chem. Soc. 136(3), 838–41 (2014).
  Medline CASGoogle Scholar
• 33 Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich's ataxia. J. Neurochem. 126(1), 142–146 (2013).
  Medline CASGoogle Scholar
• 34 Pandolfo M, Arpa J, Delatycki MD et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76(4), 509–521 (2014).
  Medline CASGoogle Scholar
• 35 Velasco-Sanchez D, Aracil A, Montero R et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10(1), 1–8 (2011).
  Medline CASGoogle Scholar
• 36 Pandolfo M, Igoillo-Esteve M, Hu A et al. Study of beta cells and neurons indicate incretin analogs as potential therapeutics for Friedreich's ataxia. Neurology 84(14), Suppl. S32.005 (2015).
  MedlineGoogle Scholar
• 37 Igoillo-Esteve M, Gurgul-Convey E, Hu A et al. Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia. Hum. Mol. Genet. 24(8), 2274–2286 (2015).
  Medline CASGoogle Scholar
• 38 Cnop M, Igoillo-Esteve M, Rai M et al. Central role and mechanism of β-cell dysfunction and death in Friedreich ataxia-associated diabetes. Ann. Neurol. 72(6), 971–982 (2012).
  Medline CASGoogle Scholar
• 39 Marmolino D, Fabio Pinelli M et al. PPAR-γ agonist azelaoyl PAF Increases frataxin protein and mRNA expression. New implications for the Friedreich ataxia therapy. Cerebellum 8, 98–103 (2009).
  Medline CASGoogle Scholar
• 40 Paupe V, Dassa EP, Goncalves S et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS ONE 4, 4253–4264 (2009).
  Google Scholar
• 41 Sturm B, Stupphann D, KAUN C et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest. 35(11), 711–717 (2005).
  Medline CASGoogle Scholar
• 42 Boesch S, Strum B, Hering S, Goldenberg H, Poeve W, Scheiber-Mojdehkar B. Friedreich ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62(5), 521–524 (2007).
  Medline CASGoogle Scholar
• 43 Boesch S, Nachnauer W, Mariotti C et al. Safety and tolerability of carbamylated erythropoietin in Friedreich ataxia. Mov. Disord. 29(7), 935–939 (2014).
  Medline CASGoogle Scholar
• 44 Mariotti C, Francellu R, Caldarazzo S et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov. Disord. 3(27), 446–449 (2012).
  Google Scholar
• 45 Rufini A, Fortuni S, Arcuri G et al. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. Hum. Mol. Genet. 20(7), 1253–1261 (2011).
  Medline CASGoogle Scholar
• 46 Sanz-Gallego I, Torres-Aleman I, Arpa J. IGF-1 in Friedreich's ataxia – proof-of-concept trial. Cerebellum Ataxias. 1(10), doi:10.1186/2053-8871-1-10 (2014).
  Google Scholar
• 47 Gottesfeld JM, Rusche JR, Pandolfo M. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich ataxia. J. Neurochem. 126(10), 147–154 (2013).
  Medline CASGoogle Scholar
• 48 Silva AM, Brown JM, Buckle VJ, Wade-Martins R, Lufino MM. Expended GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells. Hum. Mol. Genet. 24(12), 3457–3471 (2015).
  Medline CASGoogle Scholar
• 49 Libri V, Yandim C, Athanasopoulos S et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich ataxia: an exploratory, open-label, dose escalation study. Lancet 384, 504–513 (2014).
  Medline CASGoogle Scholar
• 50 Herman D, Jenssen K, Burnett R et al. Histine deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2(10), 551–558 (2006).
  Medline CASGoogle Scholar
• 51 Gottesfeld JM, Rusche JR, Pandolfo M. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich ataxia. J. Neurochem. 126(1), 147–154 (2013). •• An in-depth review of HDAC inhibitors, their effectiveness and the prospect of future clinical studies.
  Medline CASGoogle Scholar
• 52 Rai M, Soragni E, Jenssen K et al. HDAC inhibitors correct frataxin deficiency in a Friedreich mouse model. PLoS ONE 3(4), e1958 (2008).
  MedlineGoogle Scholar
• 53 Schmitz-Hubsch T, Giunti P, Stephenson DA et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71, 486–492 (2008).
  Medline CASGoogle Scholar
• 54 Tomassini B, Arcuri G, Fortuni S et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum. Mol. Genet. 21, 2855–2861 (2012). • Provides detailed information on Interferon gamma and its potential as an effective treatment of Friedreich's ataxia.
  Medline CASGoogle Scholar
• 55 Seyer L, Greeley N, Foerster D et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol. Scand. 132(1), 7–15 (2015).
  Medline CASGoogle Scholar
• 56 Arpa J, Sanz-Gallego I, Rodriguez-de-Rivera FJ et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia – open-label trial. Acta. Neurol. Scand. 129, 32–40 (2014).
  Medline CASGoogle Scholar
• 57 Arpa J, Sanz-Gallego I, Rodriguez-de-Rivera FJ et al. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial. Cerebellum 12, 713–720 (2013).
  Medline CASGoogle Scholar
• 58 Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Databse Syst. Rev. 2, CD001499 (2001).
  Google Scholar
• 59 Wessel k, Langenberger K, Nitschke M et al. Double-blind crossover study with physostigimine in patients with degenerative cerebellar disease. Arch. Neurol. 54(4), 397–400 (1997).
  Medline CASGoogle Scholar
• 60 Rodriguez-Budelli M, Kark RAP, Blass JP, Spence MA. Action of physostigmine on inherited ataxia. Adv. Neurol. 21, 195–204 (1978).
  Medline CASGoogle Scholar
• 61 Kark RAP, Budelli MMR, Wachsner R. Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias. Neurology 31, 288–292 (1981).
  Medline CASGoogle Scholar
• 62 Ristori G, Romano S, Visconti A et al. Riluzole in cerebellar ataxia. Neurology 74, 839–845 (2010).
  Medline CASGoogle Scholar
• 63 Romano S, Coarelli G, Marcotulli C et al. Riluzole in patients with hereditary cerebellar ataxia: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985–991 (2015).
  Medline CASGoogle Scholar
• 64 Alviña K, Khodakhah K. Selective regulation of spontaneous activity of neurons if the deep cerebellar nuclei by N-type calcium channels in juvenile rats. J. Physiol. 10, 2523–2538 (2008).
  Google Scholar
• 65 Feng S, Jaeger D. The role of SK calcium-dependent potassium currents on regulating the activity of deep cerebellar nucleus neurons: a dynamic clamp study. Cerebellum 7(4), 542–543 (2008).
  Medline CASGoogle Scholar
• 66 Cao YJ, Dreixler JC, Couey JJ, Houamed KM. Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur. J. Pharmacol. 449, 47–54 (2002).
  Medline CASGoogle Scholar
• 67 Zesiewicz T, Greenstein PE, Sullivan KL et al. A randomized trail varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78(8), 545–550 (2012).
  Medline CASGoogle Scholar
• 68 Clinical Trials Database. Identifier: NCT00803868. https://clinicaltrials.gov/ct2/show/NCT00803868.
  Google Scholar
• 69 Peterson PL, Saad J, Nigro MA. The treatment of Friedeich's ataxia with amantadine. Neurology 38, 1478–1480 (1988).
  Medline CASGoogle Scholar
• 70 Filla A, De Michele G, Orefice G et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can. J. Neurol. Sci. 20, 52–55 (1993).
  Medline CASGoogle Scholar
• 71 Ilg W, Synofzik M, Brötz D, Burkard S, Giese MA, Schöls L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73, 1823–1830 (2009).
  Medline CASGoogle Scholar
• 72 Ilg W, Synofzik M, Brötz D, Burkard S, Giese MA, Schöls L. Long-term effects of coordinative training in degenerative cerebellar disease. Movm. Disord. 25, 2239–2246 (2010).
  MedlineGoogle Scholar
• 73 Synofzik M, Ilg W. Motor training in degenerative spinocerebellar disease: Ataxia-specific improvements by intensive physiotherapy and exergames. Biomed. Res. Int. doi:10.1155/2014/583507 (2014).
  MedlineGoogle Scholar
• 74 Ilg W, Schatton C, Schicks j et al. Video game-based coordinative training improves ataxia in children with degenerative ataxia. Neurology 79(20), 2056–2060 (2012).
  MedlineGoogle Scholar
• 75 Synofzik M, Schatton C, Giese M et al. Videogame-based coordinative training can improve advanced, multisystemic early-onset ataxia. J. Neurol. 260(10), 2656–2658 (2013).
  MedlineGoogle Scholar
• 76 Perdomini M, Belbellaa B, Monassier L et al. Prevention and reversal of severe mitochondiral cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat. Med. 20, 542–547 (2014). •• Provides information on promising research in gene therapy for treating cardiomyopathy in the Friedreich's ataxia population.
  Medline CASGoogle Scholar
• 77 Li Y, Polak U, Bhalla AD et al. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich's ataxia. Mol. Ther. 23(6), 1055–1065 (2015).
  Medline CASGoogle Scholar
• 78 Groh M, Lufino MMP, Wade-Martins R et al. R-loops associated with triplet repeat expansion promote gene silencing in Friedreich ataxia and fragile X syndrome. PLOS Genetics 10(5), 1–13 (2014).
  Google Scholar
• 79 Yoon H, Knight SAB, Pandey A et al. Frataxin-bypassin Isu1: characterization of the bypass activity in cells and mitochondria. Biochem. J. 459(1), 71–81 (2014).
  Medline CASGoogle Scholar
• 80 Buyse G, Mertens L, Di Salvo G et al. Idebenone treatment in Friedreich ataxia: neurological, cardiac and biochemical monitoring. Neurology 60(10), 1679–1681 (2003).
  Medline CASGoogle Scholar
• 81 Rustin P, von Kliest-Retzow JC, Chantrel-Groussard K et al. Effect of idebenone on cardiomyopathy in Friedreich ataxia: a preliminary study. Lancet 354(9177), 477–479 (1999).
  Medline CASGoogle Scholar
• 82 Boddaert N, Le Quan Sang KH, Rötig A et al. Antioxidant treatment of patients with Friedreich ataxia: four year follow up. Arch. Neurol. 62(4), 621–626 (2005).
  MedlineGoogle Scholar
• 83 The Friedreich's Ataxia Treatment Pipeline is a visual tool for communicating the progress of research and development on lead therapeutic candidates. www.curefa.org/pipeline.
  Google Scholar